Welcome to our dedicated page for PALATIN TECHNOLOGIES SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palatin Technologies filings document regulatory disclosures for a biopharmaceutical company developing melanocortin receptor-targeted drug candidates. Its 8-K reports and proxy materials cover capital-structure actions, including a 1-for-50 reverse stock split, warrant-share issuance approvals, equity incentive plan matters and listing or trading-status notices for the company’s common stock.
The filing record also includes material-event disclosure on a research collaboration, license and patent assignment agreement with Boehringer Ingelheim for retinal disease programs, annual meeting voting results, advisory executive-compensation votes, corporate governance matters, operating and financial results, and clinical or regulatory disclosures tied to Palatin’s development pipeline.
Palatin Technologies, Inc. entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim International GmbH to develop melanocortin receptor-targeted peptides for retinal diseases, including diabetic retinopathy. Palatin will assign certain patent rights, collaborate on research at Boehringer Ingelheim’s expense for two years (with a possible six‑month extension), and is entitled to an upfront payment of €2.0 million ($2.3 million), up to €18.0 million ($20.9 million) in near‑term research milestones, and up to €260 million ($301.6 million) in development, regulatory and commercial milestones, plus tiered sales royalties subject to specified reductions. The agreement runs on a product‑by‑product, country‑by‑country basis through the applicable royalty term, with termination rights for bankruptcy or material breach and with Boehringer Ingelheim also able to terminate for any reason after a notice period. Separately, Palatin’s common stock was determined no longer suitable for listing on NYSE American due to its low selling price and now trades on OTC Markets under the symbol PTNTD.
Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split approved by shareholders and the board, expected to become effective after market on August 11, 2025, with shares trading on a split-adjusted basis on the OTCQB at market open on August 12, 2025. The company was previously determined not suitable for NYSE American listing due to a low selling price; trading was suspended May 7, 2025, and the stock has since traded on OTC Pink and then OTCQB under the symbol PTNT. The timing change reflects a delayed FINRA approval now expected after market on August 11, 2025.
Palatin Technologies completed a 1-for-50 reverse stock split approved by shareholders, effective August 8, 2025 at 5:00 p.m. ET. The action combines every 50 shares into one share while leaving the par value and other terms unchanged. Shares are expected to trade on the OTCQB on a split-adjusted basis beginning August 11, 2025 and will use the temporary ticker PTNTD for 20 trading days.
The company disclosed that NYSE American determined the common stock was no longer suitable for listing due to a low selling price and commenced delisting proceedings, with trading suspended on May 7, 2025. The stock traded on the Pink Market May 8–June 6, 2025 and has traded on the OTCQB since June 9, 2025. Fractional shares will be paid in cash based on the five-day average closing price prior to August 8, 2025.